Nadolol and Dilantin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Nadolol (nadolol) and Dilantin (phenytoin sodium). Common drug interactions include oxygen saturation decreased among females and agranulocytosis among males.

The phase IV clinical study analyzes what interactions people have when they take Nadolol and Dilantin. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Nadolol?

Nadolol has active ingredients of nadolol. It is often used in high blood pressure. eHealthMe is studying from 4,476 Nadolol users. Check the latest studies of Nadolol.

What is Dilantin?

Dilantin has active ingredients of phenytoin sodium. It is often used in epilepsy. eHealthMe is studying from 20,858 Dilantin users. Check the latest studies of Dilantin.

On Jul, 16, 2026

16 people who take Nadolol and Dilantin together, and have interactions are studied.

What are the common drug interactions of Nadolol and Dilantin, by gender? *:

female:

Oxygen saturation decreased
Headache (pain in head)
Facial pain
Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Chest pain
Nausea (feeling of having an urge to vomit)
Presyncope
Surgery
Asthenia (weakness)

male:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Back pain
Blood creatine phosphokinase increased
Blood creatine phosphokinase mb increased
Blood glucose fluctuation
Blood phosphorus decreased
Bone disorder
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)

What are the common drug interactions of Nadolol and Dilantin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Cholecystitis chronic (long lasting infection of gallbladder)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Diabetes mellitus inadequate control
Pancreatitis (inflammation of pancreas)
Pancreatitis acute (sudden inflammation of pancreas)

30-39:

n/a

40-49:

Decreased appetite
Disease progression
Fatigue (feeling of tiredness)
Fluid overload (too much fluid in the blood)
Hepatitis (inflammation of the liver)
Hypoglycaemia (deficiency of glucose in the bloodstream)
Nail bed bleeding
Pyrexia (fever)
Respiratory failure (inadequate gas exchange by the respiratory system)
Lymphadenopathy (disease or enlargement of lymph nodes)

50-59:

Dyspepsia (indigestion)
Hepatic steatosis (fatty liver disease)
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Chest pain
Nausea (feeling of having an urge to vomit)
Presyncope
Surgery
Asthenia (weakness)
Back pain
Chest discomfort

60+:

n/a

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 3 people, 18.75%
Stress And Anxiety: 1 person, 6.25%
Pain In Extremity: 1 person, 6.25%
Muscle Spasms (muscle contraction): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Nadolol and Dilantin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously